title: [Breast cancer in the male].
abstract: The aim of this study is to point out the late diagnosis and initiation of treatment in male with breast cancer. At the same time, to show the importance of the correlation between different markers in assessing the prognostic, as well as the treatment for the patient.
  
  
  METHODS
  Retrospective study on a group of 15 males with breast cancer, out of 1043 patients with the disease, in a period of 10 years. Eight patients were stage III of disease, 2 were stage II, one was stage I, and in other 3 cases the evaluation of the tumor and of the axillary lymph nodes was performed only by echography, considered stage II.
  
  
  RESULTS
  All patients underwent radically modified Madden mastectomy; 4 patients needed a partial resection of the great pectoralis muscle. Adjuvant chemotherapy was performed in 9 patients, and neoadjuvant chemotherapy in 2 cases. Three patients refused the chemotherapy, and one patient chose an alternative paramedical treatment. The treatment with Tamoxifen was done in 11 patients with high values of Progesterone and Estrogen Receptors (PR, ER). At the date of our study, 8 patients were alive, without clinical signs of disease (free of disease), while in 3 patients, alive, clinical signs of disease were detected (recurrence). Survival rate couldn't be evaluated in 4 patients.
  
  
  CONCLUSIONS
  Breast cancer in male is usually discovered in locally advanced stages, although most of the patients are regularly screened for chronic hepatitis. Use of biological markers allows a more accurate evaluation of the aggressiveness of the tumor, as well as a more specific treatment for each patient. Modified radical mastectomy type Madden remains the preferred surgical approach. Surgical approach should be considered even in locally advanced cases, as well as in elder patients.
authors.affiliation: Universitatea de Medicină şi Farmacie Gr.T. Popa Iaşi Facultatea de Medicina, Clinica a III(-a) Chirurgie.
authors.forename: C
authors.initials: C
authors.lastname: Diaconu
authors.forename: C
authors.initials: C
authors.lastname: Dogaru
authors.forename: C
authors.initials: C
authors.lastname: Coşman
authors.forename: R
authors.initials: R
authors.lastname: Livadariu
authors.forename: V
authors.initials: V
authors.lastname: Scarlat
authors.forename: L
authors.initials: L
authors.lastname: Miron
authors.forename: Irina
authors.initials: I
authors.lastname: Florea
authors.forename: Tamara
authors.initials: T
authors.lastname: Bostaca
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000097:blood; D018567:Breast Neoplasms, Male / Q000097:blood / Q000188:drug therapy / Q000401:mortality / Q000473:pathology* / Q000601:surgery*; D002277:Carcinoma / Q000097:blood / Q000188:drug therapy / Q000401:mortality / Q000473:pathology* / Q000601:surgery*; D018270:Carcinoma, Ductal, Breast / Q000473:pathology / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D057210:Delayed Diagnosis; D006801:Humans; D008297:Male; D015411:Mastectomy, Modified Radical; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000097:blood / Q000188:drug therapy / Q000401:mortality / Q000473:pathology* / Q000601:surgery*; D009367:Neoplasm Staging; D011960:Receptors, Estrogen / Q000097:blood; D011980:Receptors, Progesterone / Q000097:blood; D012189:Retrospective Studies; D016019:Survival Analysis; D013629:Tamoxifen / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D018931:Antineoplastic Agents, Hormonal; D014408:Biomarkers, Tumor; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D013629:Tamoxifen